BCL9 and neoplasm: c. into the right flanks of BALB/c mice; tumor-bearing animals were treated with vehicle control or hsBCL9CT-24 (ip., at 25 mg/kg or sc.,30 mg/kg) for 17 days hsBCL9CT-24 significantly reduced tumor volume relative to control throughout the study period (Figure 1A) and genetic knockdown of Bcl9 in CT26 also significantly reduced tumor growth in compared with non-targeting RNA (NT -shRNA) (Figure 1B).